BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18311775)

  • 1. Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease.
    Steinemann D; Cario G; Stanulla M; Karawajew L; Tauscher M; Weigmann A; Göhring G; Ludwig WD; Harbott J; Radlwimmer B; Bartram C; Lichter P; Schrappe M; Schlegelberger B
    Genes Chromosomes Cancer; 2008 Jun; 47(6):471-80. PubMed ID: 18311775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Array-CGH reveals hidden gene dose changes in children with acute lymphoblastic leukaemia and a normal or failed karyotype by G-banding.
    Kuchinskaya E; Heyman M; Nordgren A; Schoumans J; Staaf J; Borg A; Söderhäll S; Grandér D; Nordenskjöld M; Blennow E
    Br J Haematol; 2008 Mar; 140(5):572-7. PubMed ID: 18275435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
    Bergamaschi A; Kim YH; Wang P; Sørlie T; Hernandez-Boussard T; Lonning PE; Tibshirani R; Børresen-Dale AL; Pollack JR
    Genes Chromosomes Cancer; 2006 Nov; 45(11):1033-40. PubMed ID: 16897746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression analysis of chromosomal regions with gain or loss of genetic material detected by comparative genomic hybridization.
    Meléndez B; Díaz-Uriarte R; Cuadros M; Martínez-Ramírez A; Fernández-Piqueras J; Dopazo A; Cigudosa JC; Rivas C; Dopazo J; Martínez-Delgado B; Benítez J
    Genes Chromosomes Cancer; 2004 Dec; 41(4):353-65. PubMed ID: 15382261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
    Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
    J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute lymphoblastic leukemias with normal karyotypes are not without genomic aberrations.
    Usvasalo A; Räty R; Harila-Saari A; Koistinen P; Savolainen ER; Vettenranta K; Knuutila S; Elonen E; Saarinen-Pihkala UM
    Cancer Genet Cytogenet; 2009 Jul; 192(1):10-7. PubMed ID: 19480931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
    Szczepański T; Flohr T; van der Velden VH; Bartram CR; van Dongen JJ
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):37-57. PubMed ID: 11987915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
    Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR;
    Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization.
    Hosoya N; Sanada M; Nannya Y; Nakazaki K; Wang L; Hangaishi A; Kurokawa M; Chiba S; Ogawa S
    Genes Chromosomes Cancer; 2006 May; 45(5):482-94. PubMed ID: 16425296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Minimal residual disease in childhood acute lymphoblastic leukemia: diagnosis of the 21 century].
    Szczepański T; Sońta-Jakimczyk D; Van Dongen JJ
    Przegl Lek; 2003; 60 Suppl 5():1-4. PubMed ID: 14574999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
    Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
    Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
    Tagawa H
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia.
    Levett D; Middleton P; Cole M; Reid MM
    Med Pediatr Oncol; 2001 Mar; 36(3):365-71. PubMed ID: 11241438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of high-resolution comparative genomic hybridization (HR-CGH) in detection of chromosomal abnormalities in children with acute leukaemia.
    Vranova V; Mentzlova D; Oltova A; Linkova V; Zezulkova D; Filkova H; Mendelova D; Sterba J; Kuglik P
    Neoplasma; 2008; 55(1):23-30. PubMed ID: 18190236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic imbalances in T-cell acute lymphoblastic leukemia cell lines.
    Gebhart E; Thoma K; Verdorfer I; Drexler HG; Efferth T
    Int J Oncol; 2002 Oct; 21(4):887-94. PubMed ID: 12239631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.